Mounting evidence indicates that dysregulated host type I IFN production can manifest as being a critical driver of pathological blood coagulation during infection but also in such conditions as SLE and SAVI, and possibly during IFN therapy. The gene discussed is IFNA1; the disease is STING-associated vasculopathy with onset in infancy.